Stocks · News reference
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser after CFO resignation.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Akebia Therapeutics reported positive results from the Vafseo Outcomes In-Center Experience (VOICE) trial, demonstrating improved safety outcomes for dialysis patients treated with vadadustat.
Filed: 2026-10-23 AccNo: 0001517022-26-000075 Size: 149 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),